Get startedLog in
    Picture of China Biotech Services Holdings logo

    8037 — China Biotech Services Holdings Income Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for China Biotech Services Holdings, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSPRESS
    Standards:
    HKAS
    HKAS
    HKAS
    HKAS    		—
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue6241,85221270.573.5
    Cost of Revenue
    Gross Profit3581,10134.3-4.947.73
    Selling / General / Administrative Expenses
    Research And Development
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses4371,004359282133
    Operating Profit187848-147-212-59.1
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes181863-142-253-81.7
    Provision for Income Taxes
    Net Income After Taxes133706-141-252-80.8
    Minority Interest
    Net Income Before Extraordinary Items
    Net Income19.4258-95.4-198-68.8
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income19.4258-95.4-198-68.8
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS0.0220.271-0.082-0.149-0.075
    Dividends per Share